| Product name: |
Biotinylated Human CLDN18.2 (N-6His, C-Avi)V2 |
| Description: |
Biotinylated Recombinant Human CLDN18.2 is produced by our E.coli expression system and the target gene encoding extracellular is expressed with a 6His tag at the N-terminus. |
| Accession: |
P56856-2 |
| Molecular weight: |
12.6 KDa |
| Apparent molecular weight: |
13 KDa, reducing conditions |
| Purity: |
Greater than 95% as determined by reducing SDS-PAGE. |
| Endotoxin: |
Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test. |
| Storage: |
Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles. |
| Delivery condition: |
The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below. |
| Background: |
Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2. IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG. |
規(guī)格：
價(jià)格：
下載說(shuō)明 ①
在線咨詢
技術(shù)支持
